ATRX and cancer: RAD54 deletion imparts sensitivity to DNA damaging agents (Petukhova et al., 1999; Wesoly et al., 2006), causes defects in strand invasion (Renkawitz et al., 2013; Sugawara et al., 2003), leads to the accumulation of toxic HR intermediates (Shah et al., 2010a), and rad54 missense mutations have been linked to human cancers (Matsuda et al., 1999; Sridalla et al., 2024).